In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?

Abstract

In intermediate HCC stage patients, both treatments resulted in similar survival probabilities despite more advanced disease in the TARE Y-90 group. Still, TARE Y-90 was better tolerated and associated with less hospitalization and treatment sessions.